上皮间质转化相关蛋白在结肠癌及同期肝转移组织中的表达差异

目的研究结肠癌伴随肝转移患者原发灶及转移组织中E钙黏素,N黏黏素和波形蛋白的表达差异。方法选取62例结肠癌患者,分为3组:无转移的结肠癌组(n=42),伴肝转移的结肠癌原发灶组(n=20)和肝转移灶组(n=20)。用荧光定量PCR、Western blot和免疫组化法检测E钙黏素,N-钙黏素和波形蛋白的表达,及其与结肠癌临床病理特征的关系。结果伴肝转移组结肠癌较无转移结肠癌组、E-钙黏素表达下调(P<0.01),N-钙黏素和波形蛋白表达上调(P<0.05)。结肠癌原发灶与肝转移灶相比较,E-钙黏素表达平均吸光度值0.10±0.01比0.06±0.02(P<0.01);N钙黏素表达平均吸光度值0.07±0.02比0.09±0.01(P<0.05);波形蛋白表达平均吸光度值0.06±0.01比0.09±0.02(P<0.01)。E钙黏素、N钙黏素和波形蛋白的表达与TNM分期和淋巴结转移均密切相关(P<0.05)。结论 E-钙黏素,N-钙黏素和波形蛋白在结肠癌及伴随肝转移组织的表达差异对其预后可能具有重要意义。

Corrosion Inhibition Studies of Benzoxazole Derivates for N80 Steel in 1 M HCl Solution: Synthesis, Experimental, and DTF Studies

Three benzoxazole corrosion inhibitors, namely 2-(benzo [d]oxazol-2-yl)phenol (BOP), 6-(benzo [d]oxazol-2-yl)pyridin-2-ol (BOPO), and 2-(quinolin-2-yl) benzo [d]oxazole (QBO), were synthesized. Moreover, their corrosion inhibition performance for N80 steel in 1 M HCl solution at 303 K was measured by the electrochemical measurements and surface analysis studies. The results show that the inhibition efficiency of all corrosion inhibitors increases with the increase of concentration. At the same concentration, the order of inhibition efficiency is BOP < BOPO < QBO. Moreover, the studied inhibitors act as mixed-type inhibitors, and the adsorption of all inhibitors on N80 steel followed the Langmuir adsorption isotherm. Further, we have examined the effect of iodide ions on inhibition efficiency. The results show that BOP and KI are synergistic, BOPO and QBO are competitive adsorptions with KI. The quantum chemical parameters such as highest occupied molecular orbital, lowest unoccupied molecular orbital energy levels, and energy gap were calculated by the density functional theory (DTF). The relations between the inhibition efficiency and some quantum parameters have been discussed. The protective effect of the three inhibitors followed the sequence of BOP < BOPO < QBO. The results obtained from quantum chemicals and electrochemical were in reasonable agreement.

MiR-21/RASA1 axis affects malignancy of colon cancer cells via RAS pathways

AIM:To determine how the oncogene mi R-21 regulates the RAS signaling pathways and affects colon cancer cell behaviors.METHODS:RAS p21 GTPase activating protein 1(RASA1) protein expression in six colon cancer cell lines was assessed by Western blot.Colon cancer RKO cells were chosen for transfection because they are KRAS wild type colon cancer cells whose RASA1 expression is significantly decreased.RKO cells were transfected with vectors overexpressing or downregulating either mi R-21 or RASA1.Furthermore,a luciferase reporter assay was used to determine whether RASA1 is a gene target of mi R-21.Then,changes in m RNA and protein levels of RASA1,RASGTP,and other components of the RAS signaling pathways were assessed in transfected RKO cells by real-time quantitative reverse transcription-polymerase chain reaction,Western blot and immunoprecipitation.Finally,cell proliferation,apoptosis,invasion,and tumorformation ability w ere assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide dye assay,flow cytometry,transwell assay,and animal experiment,respectively.RESULTS:RASA1 protein levels were significantly decreased in RKO cells compared with the other 5 colon cancer cell lines,and RASA1 was confirmed as a target gene of mi R-21.Interestingly,RASA1 m RNA and protein levels in pre-mi R-21-LV(up-regulation of mi R-21) cells were lower than those in anti-mi R-21-LV(down-regulation of mi R-21) cells(P < 0.05).In addition,pre-mi R-21-LV or si RASA1(down-regulation of RASA1) cells showed higher cell proliferation,reduced apoptosis,increased expression of RAS-GTP,p-AKT,Raf-1,KRAS,and p-ERK1/2,and higher invasion and tumor formation ability,compared with control,antimi R-21-LV or pc DNA3.1-RASA1(up-regulation of RASA1) cells(P < 0.05).CONCLUSION:RASA1 is a target gene of mi R-21,which promotes malignant behaviors of RKO cells through regulation of RASA1 expression.

Decreased expression of DAB2IP in pancreatic cancer with wild-type KRAS

BACKGROUND: KRAS mutation plays an important role in the pathogenesis of pancreatic cancer. However, the role of wild-type KRAS in the progression of pancreatic cancer remains unknown. The present study was to investigate the expression of the Ras GTPase activating protein (DAB2IP) in pancreatic cancer and its clinical significance. METHODS: The expression of DAB2IP in pancreatic cancer cell lines and normal human pancreatic ductal epithelial cells was analyzed by Western blotting and realtime quantitative reverse transcription-PCR (qRT-PCR). The KRAS mutational types of pancreatic cancer tissues obtained from pancreatic cancer patients (n=20) were also analyzed. Subsequently, DAB2IP expression was detected in pancreatic cancer tissues, adjacent and normal pancreatic tissues (n=2) by immunohistochemistry, and the relationship between DAB2IP expression and the clinical characteristics of patients was evaluated. RESULTS: Western blotting and qRT-PCR results showed that DAB2IP expression in pancreatic cancer cells with wild-type KRAS was lower than that in those with mutation-type KRAS and normal human pancreatic ductal epithelial cells (P【0.05). Immunohistochemistry showed that DAB2IP expression was lower in pancreatic cancer tissues than that in adjacent and normal pancreatic tissues (Z=-4.000, P=0.000). DAB2IP expression was lower in pancreatic cancer patients with the wild-type KRAS gene than that in those with KRAS mutations (WilcoxonW=35.000, P=0.042). Furthermore,DAB2IP expression in patients with perineurial invasion was lower than that in those without invasion (WilcoxonW=71.500, P=0.028). DAB2IP expression was lower in patients with more advanced stage than that in those with early clinical stage (WilcoxonW=54.000, P=0.002). CONCLUSIONS: DAB2IP expression was reduced in patients with pancreatic cancer compared with those with no cancer. DAB2IP expression was correlated with the KRAS gene, perineurial invasion and clinical stage of the disease. Our data indicated that DAP2IP expression can be used as a potential prognostic indicator and a promising molecular target for therapeutic intervention in patients with pancreatic cancer.

Nitrogen and Sulfur Co-doped Porous Carbon Derived from ZIF-8 as Oxygen Reduction Reaction Catalyst for Microbial Fuel Cells

Nitrogen and sulfur co-doped porous nanocarbon (ZIF-C-N-S) catalyst was successfully synthesized derived from ZIF-8 and thiourea precursors.The electrochemical measurements indicate that the as-obtained ZIF-C-N-S catalyst exhibits higher electrocatalytic activity for oxygen reduction reaction (ORR) in alkaline electrolyte and superior durability-longer than commercial Pt/C catalyst.The enhancment of electrocatalytic activity mainly be come from the open pore structure,large specific surface area as well as the synergistic effect resulted from the co-doping of N and S atoms.In addition,the ZIF-C-N-S catalyst is also used as the air cathode catalyst in the microbial fuel cell (MFC) device.The maximum power density and stable output voltage of ZIF-C-N-S based MFC are 1315 mW/m2 and 0.48 V,respectively,which is better than that of Pt/C based MFC.

阿司匹林联合阿托伐他汀治疗高血压合并糖尿病的效果观察

目的探讨阿司匹林联合阿托伐他汀治疗高血压合并糖尿病的临床效果。方法选取2016年1月至2017年12月山西医科大学第一医院收治的高血压合并糖尿病患者100例,按照随机数字表法分为阿司匹林组和阿司匹林联合阿托伐他汀治疗组(联合治疗组),每组50例。阿司匹林组给予拜阿司匹林(100 mg/d)治疗,联合治疗组给予拜阿司匹林(100 mg/d)+阿托伐他汀(20 mg/d)治疗。测定并比较两组治疗前及治疗后20周的血脂、尿白蛋白、β2微球蛋白(β2-MG)、尿白蛋白排泄率(UAER)、心踝血管指数(CAVI)、踝臂指数(ABI),通过随访对其非致死性心肌梗死发生率进行对比分析。结果与治疗前比较,两组患者总胆固醇和低密度脂蛋白胆固醇水平降低,CAVI和ABI水平得到改善,差异有统计学意义(P<0.05);且联合治疗组CAVI和ABI水平改善程度优于阿司匹林组(P<0.05)。治疗后,阿司匹林组高密度脂蛋白胆固醇、尿白蛋白、β2-MG、三酰甘油、UAER与治疗前比较差异未见统计学意义(P>0.05);而联合治疗组尿白蛋白、三酰甘油、UAER、β2-MG均低于治疗前(P均<0.05)。阿司匹林组非致死性心肌梗死主要终点的发生率高于联合治疗组(P<0.05)。通过多元逐步回归分析发现,影响动脉僵硬度和微量蛋白尿的危险因素为舒张压、收缩压、餐后2 h血糖以及空腹血糖。结论阿司匹林与阿托伐他汀合用能够降低高血压合并糖尿病患者尿微量蛋白水平,明显缓解动脉僵硬度,有效减少非致死性心肌梗死主要终点发生率,并发现动脉僵硬度及微量蛋白尿与血压及血糖水平具有直接关系。

Oxide Inclusions in Ferromanganese and Its Influence on the Quality of Clean Steels

Low and medium carbon ferromanganese produced by oxygen decarburization process and electric silicothermic process was briefly introduced, and the quality of products by these two processes was analyzed. Results showed that the total oxygen content in medium carbon ferromanganese by electric silicothermic process in China, which ranged from 0.039% to 0.171%, was between those of the common and refined products by oxygen decarburization process outside of China. The increments of total oxygen content in liquid steel were estimated when ferromanganese was added for the purpose of Mn element adjustment at the end of smelting. Refined low and medium carbon ferromanganese, which had low total oxygen content, was recommended for composition adjustment of clean steels during final stage of a heat. It is possible that the inclusions in the ferromanganese alloy greatly influenced the quality of clean steel indirectly by affecting the amount, size and composition of inclusions in steel.